Research programme: phosphodiesterase 10 inhibitors - Celon Pharma

Drug Profile

Research programme: phosphodiesterase 10 inhibitors - Celon Pharma

Alternative Names: PDE10 inhibitors - Celon Pharma; Phosphodiesterase 10A inhibitors - Celon Pharma

Latest Information Update: 29 Dec 2015

Price : $50

At a glance

  • Originator Celon Pharma
  • Class Antipsychotics
  • Mechanism of Action Phosphodiesterase 10A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Huntington's disease; Psychotic disorders

Most Recent Events

  • 13 May 2015 Early research in Psychotic disorders in Poland (unspecified route)
  • 13 May 2015 Early research in Huntington's disease in Poland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top